Endocrinol Metab.  2020 Sep;35(3):549-551. 10.3803/EnM.2020.308.

Why Do We Need Proactive Management for Fracture Prevention in Long-Term Glucocorticoid Users?

• Choi HS

• KMID: 2508003
• DOI: http://doi.org/10.3803/EnM.2020.308

Reference

1. Timmermans S, Souffriau J, Libert C. A general introduction to glucocorticoid biology. Front Immunol. 2019; 10:1545.

2. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology (Oxford). 2011; 50:1982–90.

3. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res (Hoboken). 2013; 65:294–8.

4. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine. 2018; 61:7–16.

5. Kanis JA, Johansson H, Oden A, Johnell O, de Laet C, Melton LJ III, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 19:893–9.

6. Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Levesque LE, Adachi JD, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016; 27:1709–18.

7. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006; 39:253–9.

8. Kanis JA, Johansson H, Oden A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011; 22:809–16.

9. Koh JW, Kim J, Cho H, Ha YC, Kim TY, Lee YK, et al. Effects of systemic glucocorticoid use on fracture risk: a population-based study. Endocrinol Metab. 2020; 35:562–70.

10. Curtis JR, Westfall AO, Allison JJ, Becker A, Casebeer L, Freeman A, et al. Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients. Arthritis Rheum. 2005; 52:2485–94.

11. Curtis JR, Westfall AO, Allison JJ, Freeman A, Saag KG. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int. 2006; 17:1268–74.